Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis

Abstract

Abstract We read the excellent viewpoint by Slavin et al. (J Antimicrob Chemother 2022; 77: 16–23) that draws upon the experience of an advisory board of notable experts to comprehensively address many of the clinical factors that drive the need for changes in antifungal therapy for invasive aspergillosis (IA). As noted by the authors, there remains a paucity of quality data to support many of the decisions faced by clinicians managing patients with IA. However, we would like to highlight several other important issues, not fully addressed in that viewpoint, that play an important role in deciding when to change antifungal therapy for IA.